AavantiBio and Catalent Announce Partnership to Support Development and Manufacturing of Gene Therapies for Rare Genetic Diseases
Share Article
AavantiBio, a gene therapy company focused on transforming the lives of patients with rare genetic diseases, and Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced a partnership to support the development and manufacturing of AavantiBio’s gene therapies, including its lead program in Friedreich’s Ataxia (FA).
Our development team at the University of Maryland BioPark is focused on providing process optimization services to meet our customers’ needs and partnering with them to bring innovative therapies to patients faster
AavantiBio Deepens AAV Manufacturing Capabilities with Key Hires to Support Strategic Growth
yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.
Manalapan charity will run drug trial on Duchenne muscular dystrophy
app.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from app.com Daily Mail and Mail on Sunday newspapers.
Shares of Solid Biosciences (
SLDB) - Get Report dropped Tuesday after the developer of a Duchenne muscular-dystrophy treatment reported that a patient had an adverse event in an trial of its gene-therapy candidate.
The Cambridge, Mass., company said that six patients in its ongoing clinical study showed promising results.
A seventh patient was safely dosed, with transient and manageable adverse events, none of which were serious, it said in a statement The totality of data collected, and the reinitiation of dosing, support the continued enrollment of patients into the Ignite DMD study, the company said. We are encouraged with the successful resumption of dosing in the Ignite DMD trial under our amended clinical protocol and using SGT-001 manufactured with a second-generation process, Barry Byrne, a physician who is principal investigator of the study, said.
Solid Biosciences Reports Efficacy and Safety Data from the Ongoing IGNITE DMD Clinical Trial and Resumption of Patient Dosing in the 2E14 vg/kg Cohort
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.